Biotech-365

biotech-365.com

Biotech 365 is an independent website, sharing information and news about Biotech and Biopharma : innovative Biotech companies, Biotech Jobs, Biotech tools, Bioinformatic softwares, Biopharma news, etc.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

BIOVAXYS AND PROCARE HEALTH EXECUTE US DISTRIBUTION AGREEMENT FOR PAPILOCARE GEL AND ORAL IMMUNOCAPS

BioVaxys Technology Corp. | December 20, 2022

news image

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction. Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product wit...

Read More

Cell and Gene Therapy

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

news image

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More

Industrial Impact

WUXI XDC AND ABTIS SIGN MEMORANDUM OF UNDERSTANDING FOR DEVELOPMENT AND MANUFACTURING OF ANTIBODY DRUG CONJUGATES

WuXi Biologics | July 08, 2022

news image

WuXi XDC, a global leading CRDMO dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates announced that a Memorandum of Understanding was signed to form a strategic partnership in AbTis' portfolio of ADC products. Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process development, ADC formulation a...

Read More

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

news image

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More
news image

Industrial Impact, Medical

BIOVAXYS AND PROCARE HEALTH EXECUTE US DISTRIBUTION AGREEMENT FOR PAPILOCARE GEL AND ORAL IMMUNOCAPS

BioVaxys Technology Corp. | December 20, 2022

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction. Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product wit...

Read More
news image

Cell and Gene Therapy

TAIGEN PARTNERS WITH GPCR TO DEVELOP BURIXAFOR & TAIGEXYN(R)

Burixafor | November 09, 2020

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantatio...

Read More
news image

Industrial Impact

WUXI XDC AND ABTIS SIGN MEMORANDUM OF UNDERSTANDING FOR DEVELOPMENT AND MANUFACTURING OF ANTIBODY DRUG CONJUGATES

WuXi Biologics | July 08, 2022

WuXi XDC, a global leading CRDMO dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates announced that a Memorandum of Understanding was signed to form a strategic partnership in AbTis' portfolio of ADC products. Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process development, ADC formulation a...

Read More
news image

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us